Literature DB >> 33740082

[From the evidence to recommendations-how to skillfully justify guideline recommendations].

Monika Nothacker1.   

Abstract

To justify clinical guideline recommendations comprehensibly is challenging. It is a matter of presenting the quality of the published evidence concerning its certainty and patient relevance, but also additional reasons for the grade of recommendation, as the strength of the recommendation does not only reflect the strength of the evidence. To state this reasoning in a structured manner, an "Evidence to Decision Framework" was developed. In addition to an evaluation of benefits and harms as well as information on certainty of the evidence, the framework comprises further criteria as patient preferences, acceptance of professional stakeholders, feasibility, equity and resources and costs. The most important arguments to justify recommendations in exemplary analyzed urological guidelines are the balance of benefits and harms and the appraisal of the certainty of the underlying evidence; in some cases, patient preferences are addressed. Whether there is an added value in applying further decision criteria for the development and implementation of guidelines remains to be verified. An opportunity of S3 guidelines (evidence- and consensus-based, 6/17 urological guidelines) is that knowledge gaps can be systematically identified, which enables the formulation of relevant research questions, which may contribute to a better basis for future recommendations.

Entities:  

Keywords:  Benefits and harms; Certainty of the evidence; Criteria; Grade of recommendation; Patient relevance

Year:  2021        PMID: 33740082     DOI: 10.1007/s00120-021-01493-w

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  9 in total

1.  GRADE guidelines: 2. Framing the question and deciding on important outcomes.

Authors:  Gordon H Guyatt; Andrew D Oxman; Regina Kunz; David Atkins; Jan Brozek; Gunn Vist; Philip Alderson; Paul Glasziou; Yngve Falck-Ytter; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2010-12-30       Impact factor: 6.437

2.  GRADE guidelines: 3. Rating the quality of evidence.

Authors:  Howard Balshem; Mark Helfand; Holger J Schünemann; Andrew D Oxman; Regina Kunz; Jan Brozek; Gunn E Vist; Yngve Falck-Ytter; Joerg Meerpohl; Susan Norris; Gordon H Guyatt
Journal:  J Clin Epidemiol       Date:  2011-01-05       Impact factor: 6.437

3.  GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength.

Authors:  Jeffrey C Andrews; Holger J Schünemann; Andrew D Oxman; Kevin Pottie; Joerg J Meerpohl; Pablo Alonso Coello; David Rind; Victor M Montori; Juan Pablo Brito; Susan Norris; Mahmoud Elbarbary; Piet Post; Mona Nasser; Vijay Shukla; Roman Jaeschke; Jan Brozek; Ben Djulbegovic; Gordon Guyatt
Journal:  J Clin Epidemiol       Date:  2013-04-06       Impact factor: 6.437

4.  GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines.

Authors:  Pablo Alonso-Coello; Andrew D Oxman; Jenny Moberg; Romina Brignardello-Petersen; Elie A Akl; Marina Davoli; Shaun Treweek; Reem A Mustafa; Per O Vandvik; Joerg Meerpohl; Gordon H Guyatt; Holger J Schünemann
Journal:  BMJ       Date:  2016-06-30

5.  Do clinicians want recommendations? A multicenter study comparing evidence summaries with and without GRADE recommendations.

Authors:  Ignacio Neumann; Pablo Alonso-Coello; Per Olav Vandvik; Thomas Agoritsas; Gemma Mas; Elie A Akl; Romina Brignardello-Petersen; Jose Emparanza; Lauren McCullagh; Catherine De Sitio; Thomas McGinn; Hind Almodaimegh; Khalid Almodaimegh; Solange Rivera; Luis Rojas; Jérôme Stirnemann; Jihad Irani; Sani Hlais; Reem Mustafa; Fadi Bdair; Abdelrahman Aly; Annette Kristiansen; Ariel Izcovich; Anggie Ramirez; Jan Brozek; Gordon Guyatt; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2018-03-09       Impact factor: 6.437

Review 6.  EAU guidelines on renal cell carcinoma: 2014 update.

Authors:  Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex
Journal:  Eur Urol       Date:  2015-01-21       Impact factor: 20.096

7.  GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence.

Authors:  Holger J Schünemann; Carlos Cuello; Elie A Akl; Reem A Mustafa; Jörg J Meerpohl; Kris Thayer; Rebecca L Morgan; Gerald Gartlehner; Regina Kunz; S Vittal Katikireddi; Jonathan Sterne; Julian Pt Higgins; Gordon Guyatt
Journal:  J Clin Epidemiol       Date:  2018-02-09       Impact factor: 6.437

8.  GRADE equity guidelines 4: considering health equity in GRADE guideline development: evidence to decision process.

Authors:  Kevin Pottie; Vivian Welch; Rachael Morton; Elie A Akl; Javier H Eslava-Schmalbach; Vittal Katikireddi; Jasvinder Singh; Lorenzo Moja; Eddy Lang; Nicola Magrini; Lehana Thabane; Roger Stanev; Elizabeth Matovinovic; Alexandra Snellman; Matthias Briel; Beverly Shea; Peter Tugwell; Holger Schunemann; Gordon Guyatt; Pablo Alonso-Coello
Journal:  J Clin Epidemiol       Date:  2017-08-10       Impact factor: 6.437

Review 9.  Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review.

Authors:  Su Golder; Yoon K Loke; Kath Wright; Gill Norman
Journal:  PLoS Med       Date:  2016-09-20       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.